BioCryst Projects Strong Growth for ORLADEYO in 2025

Published 6 hours agoBCRX

BioCryst Projects Strong Growth for ORLADEYO in 2025

BioCryst Pharmaceuticals has announced promising growth projections for its drug ORLADEYO (berotralstat). In 2024, ORLADEYO's net revenue climbed to $437 million, reflecting a 34% increase from the previous year. This upward trend is expected to continue as the company provides guidance for 2025, anticipating net revenue between $515 million and $535 million, which would indicate growth of approximately 33-37% from 2024 figures.

Looking further into the future, BioCryst is targeting peak annual sales of $1 billion for ORLADEYO by 2029. As part of its strategy to expand market presence, the company plans to submit a new drug application for ORLADEYO in a granule form specifically designed for children under 12 years old. This initiative aims to meet significant unmet needs within this demographic. Additionally, BioCryst is actively developing new treatments, advancing clinical programs for BCX17725, targeting Netherton syndrome, and avoralstat for diabetic macular edema, with initial data anticipated by the end of the year.

Reuters reported that these strategic initiatives highlight BioCryst's commitment not only to scaling the presence of ORLADEYO but also to advancing its overall therapeutic pipeline. By pursuing these goals, the company demonstrates a focused approach in expanding its contributions to unmet medical needs and growing its market share.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Hims & Hers Health Sees Strong Q1 Growth Amid Stock Dip

Hims & Hers Health Sees Strong Q1 Growth Amid Stock Dip

8 minutes agoHIMS

Hims & Hers Health, Inc. (NYSE: HIMS) recently announced robust financial results for the first quarter of 2025, reporting a significant 46% increase in revenue year-over-year to $278 million. Despite showcasing a notable turnaround with a net income of $11.1 million, recovering from a loss in the same period last year, the company saw its stock price decline in post-market trading. The company's growth momentum is evident as their subscriber base expanded to over 1.7 million, marking a 41% increase compared to the previous year. Investing.com highlighted that Hims & Hers is not only focusing on financial performance but is also planning strategic expansions, such as introducing new product offerings in weight loss and dermatology, and investing in affiliated pharmacies to boost operational efficiency. Looking ahead in 2025, Hims & Hers projects its annual revenue to range between $2.3 billion and $2.4 billion with an expected adjusted EBITDA of $270 million to $320 million. Even though the company's financial outlook remains positive, the decline in its stock price, closing at $41.88 and down 2.76%, indicates that investors are carefully evaluating these achievements against broader market conditions.

Neurocrine Biosciences Sees Stock Surge After Strong Q1 Results

Neurocrine Biosciences Sees Stock Surge After Strong Q1 Results

23 minutes agoNBIX

Neurocrine Biosciences (NBIX) experienced a notable 13% increase in its stock price following the release of impressive first-quarter financial results for 2025. According to Webull, key figures include net product sales of INGREZZA reaching $621.2 million in Q4 2024, reflecting a 23% year-over-year growth. This robust performance has bolstered market confidence in the company. Moreover, Neurocrine has set ambitious sales projections for INGREZZA for the full year 2025, with anticipated net product sales ranging between $2.5 billion and $2.6 billion, as reported by Market Screener. Additionally, the company has recently launched CRENESSITY, an FDA-approved groundbreaking treatment for congenital adrenal hyperplasia, marking a significant expansion of its product portfolio. Plans are also underway for Phase 3 program initiations for two other treatments: osavampator for major depressive disorder and NBI-568 for schizophrenia within the first half of this year. These developments are part of Neurocrine's strategic focus on expanding its influence in the neuroscience sector. By enhancing its product offerings and advancing its pipeline initiatives, the company demonstrates ongoing commitment to addressing critical health conditions, painting a promising picture for its growth trajectory.

Bristol Myers Squibb to Invest $40 Billion in U.S. Over Five Years

Bristol Myers Squibb to Invest $40 Billion in U.S. Over Five Years

38 minutes agoBMY

Bristol Myers Squibb (BMS) has unveiled plans to invest a significant $40 billion in the United States over the next five years. This major financial commitment is aimed at bolstering research and development, enhancing technology, and expanding domestic manufacturing capabilities. As Reuters reported, this investment is part of the company's broader strategy to reinforce its U.S. operations. The initiative is designed to improve BMS's control over its supply chain while accelerating innovation through the adoption of artificial intelligence and machine learning. Part of this funding will be directed towards scaling up radiopharmaceutical manufacturing, a step following BMS's acquisition of RayzeBio for $4.1 billion in 2024. This acquisition has already expanded the company's pipeline with multiple radiopharma drug candidates. This announcement comes against the backdrop of potential tariffs threatened by President Donald Trump due to national security concerns. The administration has responded by signing an executive order to hasten pharmaceutical plant approvals, encouraging domestic production. BMS's move represents a clear commitment to strengthening its foothold and capabilities in the U.S. pharmaceutical sector.

Mattel Adjusts Strategy Amid Rising Tariff Costs

Mattel Adjusts Strategy Amid Rising Tariff Costs

52 minutes agoMAT

Mattel Inc., known for its iconic Barbie and Hot Wheels brands, has announced a shift in its pricing and production strategies due to heightened tariffs. The company plans to raise prices on select U.S. products in response to a 145% tariff imposed on most Chinese goods by U.S. President Donald Trump. This measure is aimed at counterbalancing the increased costs associated with these tariffs, as reported by the Associated Press. In addition to price hikes, Mattel is speeding up its plans to reduce reliance on Chinese manufacturing. By the year's end, the company expects to operate only one factory in China, significantly down from four. This move is part of a broader diversification strategy to mitigate risks associated with trade tensions. The Financial Times noted that the unpredictability of these trade policies has led Mattel to suspend its annual earnings forecast, reflecting the challenges of projecting U.S. sales and consumer spending. In the first quarter that ended on March 31, Mattel saw a 2% increase in sales, reaching $827 million, but recorded a net loss of $40.3 million compared to a $28.3 million loss in the previous year's similar period. Following the strategic announcements, Mattel's stock experienced nearly a 3% drop in after-market trading, indicating investor concerns over the uncertainties ahead.